Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030004/S035

Onyx Liquid Embolic System (LES)

Ev3 Neurovascular · Decision date Dec 8, 2025

FDA DECISIONP030004/S035

What did the FDA approve?

FDA records P030004/S035 as a supplement to PMA P030004, with the supplement type “Panel Track”. The recorded decision is approval, dated Dec 8, 2025.

FDA approval order statement

Onyx Liquid Embolic System (LES) is indicated for embolization of the middle meningeal artery (MMA) as an adjunct to surgery for the treatment of symptomatic subacute or chronic subdural hematoma (SDH).
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Neurology
Decision date
Dec 8, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P030004/S035
Regulatory pathway
PMA supplement
Product code
SGU
Decision code
APPR
Decision date
Dec 8, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Neurovascular Liquid Embolic Agent.

Product code
SGU
FDA device class
3

For the original device and its historical approval scope, see PMA P030004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030004 · Original PMA

    ONYX LIQUID EMBOLIC SYSTEM

  2. P030004/S035 received

    Application receipt date recorded by FDA.

  3. P030004/S035 · FDA decision

    Panel Track

  4. P030004/S041 · Related supplement

    Apollo Onyx Delivery Micro Catheter

  5. P030004/S040 · Related supplement

    Onyx Liquid Embolic System (LES)

  6. P030004/S043 · Related supplement

    Apollo Onyx Delivery Micro Catheter

  7. P030004/S044 · Related supplement

    Onyx Liquid Embolic System

  8. P030004/S042 · Related supplement

    Onyx Liquid Embolic System (LES)

  9. P030004/S039 · Related supplement

    Onyx Liquid Embolic System (Onyx LES)

Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030004

Product / regulatory recordCompanyPathwayDecision dateSource
Ev3 NeurovascularPMA approvalJul 21, 2005FDA
Ev3 NeurovascularPMA supplementApr 9, 2026FDA
Ev3 NeurovascularPMA supplementApr 29, 2026FDA
Ev3 NeurovascularPMA supplementMay 26, 2026FDA
Ev3 NeurovascularPMA supplementJul 21, 2026FDA
Ev3 NeurovascularPMA supplementAug 5, 2026FDA
Ev3 NeurovascularPMA supplementOct 14, 2026FDA

Explore the linked device profile

Other records with product code SGU

Product / regulatory recordCompanyPathwayDecision dateSource
Balt USA, LLCPMA supplementOct 16, 2026FDA
Balt USA, LLCPMA supplementSep 9, 2026FDA
Balt USA, LLCPMA approvalJan 30, 2026FDA
Cerenovus, Inc.PMA supplementDec 16, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ev3 Neurovascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9775 Toledo Way, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records